A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Phase 3

Completed

• Conditions: Glaucoma, Open-Angle; Ocular Hypertension

• Registration Number: NCT00051142
• Lead Sponsor: Alcon Research

Brief Summary

The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-02
• Study First Submitted: 2003-01-03
• Study First Submitted QC: 2003-01-06
• Study First Posted: 2003-01-07
• Primary Completion: 2004-06
• Study Completion: 2004-06
• Status Verified: 2008-08
• Last Update Submitted: 2008-08-04
• Last Update Posted: 2008-08-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

Latin America; 🇺🇸 Fort Worth, Texas, United States